Medve Robert 4
4 · NEKTAR THERAPEUTICS · Filed Feb 8, 2013
Insider Transaction Report
Form 4
Medve Robert
Chief Medical Officer
Transactions
- Award
Stock Option
2013-02-06+50,000→ 50,000 totalExercise: $8.80Exp: 2021-02-05→ Common Stock (50,000 underlying) - Award
Stock Option
2013-02-06+50,000→ 50,000 totalExercise: $8.80Exp: 2021-02-05→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]This option was granted on February 6, 2013 and vests in monthly installments over the four-year period following the grant date.
- [F2]This stock option is subject to both time-based vesting and performance-based vesting conditions, both of which must be met before the shares subject to the option become vested and exerciseable. The time-based vesting is on a monthly pro-rata basis over a period of four (4) years from the grant date (February 6, 2013). The performance-based vesting condition will be met only if Nektar (or a licensee) files a new drug registration with the FDA or the European Medicines Agency for a significant drug candidate program including, without limitation, the following: (1) naloxegol (an oral peripherally-acting opioid antagonist); (2) etirinotecan pegol (a topoisomerase I inhibitor); (3) NKTR-061/Amikacin Inhale (a drug-device combination for an inhaled solution of amikacin); or (4) BAX-855 (a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein).